{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T12:37:10Z","timestamp":1792931830193,"version":"4.5.0"},"reference-count":214,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T00:00:00Z","timestamp":1765152000000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National Key Research and Development Program of China","award":["2019YFA0111000"],"award-info":[{"award-number":["2019YFA0111000"]}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82470166, 82400188, 82200149, 82170158, 82100175 and 82100170"],"award-info":[{"award-number":["82470166, 82400188, 82200149, 82170158, 82100175 and 82100170"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the priority academic program development of Jiangsu Higher Education Institution, the Natural Science Foundation of Jiangsu Province","award":["BK20231195, BK20210087"],"award-info":[{"award-number":["BK20231195, BK20210087"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Precis. Onc."],"DOI":"10.1038\/s41698-025-01200-4","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T06:05:36Z","timestamp":1764914736000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Dysregulation of HOXA genes in acute myeloid leukemia and targeted therapy"],"prefix":"10.1038","volume":"9","author":[{"given":"Wusixian","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fenghong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinrong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suning","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"key":"1200_CR1","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/S0140-6736(23)00108-3","volume":"401","author":"CD DiNardo","year":"2023","unstructured":"DiNardo, C. D., Erba, H. P., Freeman, S. D. & Wei, A. H. Acute myeloid leukaemia. Lancet 401, 2073\u20132086 (2023).","journal-title":"Lancet"},{"key":"1200_CR2","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1016\/S0140-6736(18)31694-5","volume":"392","author":"KJ Foreman","year":"2018","unstructured":"Foreman, K. J. et al. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016-40 for 195 countries and territories. Lancet 392, 2052\u20132090 (2018).","journal-title":"Lancet"},{"key":"1200_CR3","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1056\/NEJMoa0901409","volume":"361","author":"B L\u00f6wenberg","year":"2009","unstructured":"L\u00f6wenberg, B. et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N. Engl. J. Med. 361, 1235\u20131248 (2009).","journal-title":"N. Engl. J. Med."},{"key":"1200_CR4","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1056\/NEJMoa0904544","volume":"361","author":"HF Fernandez","year":"2009","unstructured":"Fernandez, H. F. et al. Anthracycline dose intensification in acute myeloid leukemia. N. Engl. J. Med. 361, 1249\u20131259 (2009).","journal-title":"N. Engl. J. Med."},{"key":"1200_CR5","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo, C. D. et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N. Engl. J. Med. 383, 617\u2013629 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1200_CR6","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1158\/2159-8290.CD-19-0710","volume":"10","author":"S Pei","year":"2020","unstructured":"Pei, S. et al. Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia. Cancer Discov. 10, 536\u2013551 (2020).","journal-title":"Cancer Discov."},{"key":"1200_CR7","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/s41586-024-08137-x","volume":"636","author":"J Sango","year":"2024","unstructured":"Sango, J. et al. RAS-mutant leukaemia stem cells drive clinical resistance to venetoclax. Nature 636, 241\u2013250 (2024).","journal-title":"Nature"},{"key":"1200_CR8","doi-asserted-by":"publisher","first-page":"12223","DOI":"10.1073\/pnas.91.25.12223","volume":"91","author":"G Sauvageau","year":"1994","unstructured":"Sauvageau, G. et al. Differential expression of homeobox genes in functionally distinct CD34+ subpopulations of human bone marrow cells. Proc. Natl. Acad. Sci. USA 91, 12223\u201312227 (1994).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1200_CR9","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/sj.leu.2402354","volume":"16","author":"HA Drabkin","year":"2002","unstructured":"Drabkin, H. A. et al. Quantitative HOX expression in chromosomally defined subsets of acute myelogenous leukemia. Leukemia 16, 186\u2013195 (2002).","journal-title":"Leukemia"},{"key":"1200_CR10","doi-asserted-by":"publisher","first-page":"4461","DOI":"10.1182\/blood-2012-05-429274","volume":"120","author":"A Shi","year":"2012","unstructured":"Shi, A. et al. Structural insights into inhibition of the bivalent menin-MLL interaction by small molecules in leukemia. Blood 120, 4461\u20134469 (2012).","journal-title":"Blood"},{"key":"1200_CR11","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/s41586-023-05755-9","volume":"615","author":"F Perner","year":"2023","unstructured":"Perner, F. et al. MEN1 mutations mediate clinical resistance to menin inhibition. Nature 615, 913\u2013919 (2023).","journal-title":"Nature"},{"key":"1200_CR12","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/276565a0","volume":"276","author":"EB Lewis","year":"1978","unstructured":"Lewis, E. B. A gene complex controlling segmentation in Drosophila. Nature 276, 565\u2013570 (1978).","journal-title":"Nature"},{"key":"1200_CR13","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1093\/oxfordjournals.humrep.a136802","volume":"3","author":"E Boncinelli","year":"1988","unstructured":"Boncinelli, E. et al. Organization of human homeobox genes. Hum. Reprod. 3, 880\u2013886 (1988).","journal-title":"Hum. Reprod."},{"key":"1200_CR14","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1126\/science.1132040","volume":"313","author":"D Lemons","year":"2006","unstructured":"Lemons, D. & McGinnis, W. Genomic evolution of Hox gene clusters. Science 313, 1918\u20131922 (2006).","journal-title":"Science"},{"key":"1200_CR15","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.02557","volume":"3","author":"D Noordermeer","year":"2014","unstructured":"Noordermeer, D. et al. Temporal dynamics and developmental memory of 3D chromatin architecture at Hox gene loci. Elife 3, e02557 (2014).","journal-title":"Elife"},{"key":"1200_CR16","doi-asserted-by":"publisher","first-page":"E1913","DOI":"10.1073\/pnas.1614501114","volume":"114","author":"SM Schiemann","year":"2017","unstructured":"Schiemann, S. M. et al. Clustered brachiopod Hox genes are not expressed collinearly and are associated with lophotrochozoan novelties. Proc. Natl. Acad. Sci. USA 114, E1913\u2013e1922 (2017).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1200_CR17","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1038\/leu.2012.356","volume":"27","author":"RA Alharbi","year":"2013","unstructured":"Alharbi, R. A., Pettengell, R., Pandha, H. S. & Morgan, R. The role of HOX genes in normal hematopoiesis and acute leukemia. Leukemia 27, 1000\u20131008 (2013).","journal-title":"Leukemia"},{"key":"1200_CR18","doi-asserted-by":"publisher","first-page":"3988","DOI":"10.1182\/blood-2005-05-2003","volume":"106","author":"HJ Lawrence","year":"2005","unstructured":"Lawrence, H. J. et al. Loss of expression of the Hoxa-9 homeobox gene impairs the proliferation and repopulating ability of hematopoietic stem cells. Blood 106, 3988\u20133994 (2005).","journal-title":"Blood"},{"key":"1200_CR19","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1182\/blood.V89.6.1922","volume":"89","author":"HJ Lawrence","year":"1997","unstructured":"Lawrence, H. J. et al. Mice bearing a targeted interruption of the homeobox gene HOXA9 have defects in myeloid, erythroid, and lymphoid hematopoiesis. Blood 89, 1922\u20131930 (1997).","journal-title":"Blood"},{"key":"1200_CR20","doi-asserted-by":"crossref","unstructured":"Cieslak, A. et al. Blueprint of human thymopoiesis reveals molecular mechanisms of stage-specific TCR enhancer activation. J. Exp. Med. 217 (2020).","DOI":"10.1084\/jem.20192360"},{"key":"1200_CR21","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1182\/blood.V94.2.519.414k20_519_528","volume":"94","author":"GM Crooks","year":"1999","unstructured":"Crooks, G. M. et al. Constitutive HOXA5 expression inhibits erythropoiesis and increases myelopoiesis from human hematopoietic progenitors. Blood 94, 519\u2013528 (1999).","journal-title":"Blood"},{"key":"1200_CR22","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/S0301-472X(00)00349-0","volume":"28","author":"C Buske","year":"2000","unstructured":"Buske, C. et al. HOXA10-overexpression causes severe perturbations in human hematopoiesis. Exp. Hematol. 28, 84\u201384 (2000).","journal-title":"Exp. Hematol."},{"key":"1200_CR23","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1182\/blood.V97.8.2286","volume":"97","author":"C Buske","year":"2001","unstructured":"Buske, C. et al. Overexpression of HOXA10 perturbs human lymphomyelopoiesis in vitro and in vivo. Blood 97, 2286\u20132292 (2001).","journal-title":"Blood"},{"key":"1200_CR24","doi-asserted-by":"publisher","first-page":"3192","DOI":"10.1182\/blood-2003-10-3722","volume":"103","author":"CW So","year":"2004","unstructured":"So, C. W., Karsunky, H., Wong, P., Weissman, I. L. & Cleary, M. L. Leukemic transformation of hematopoietic progenitors by MLL-GAS7 in the absence of Hoxa7 or Hoxa9. Blood 103, 3192\u20133199 (2004).","journal-title":"Blood"},{"key":"1200_CR25","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1038\/leu.2016.240","volume":"31","author":"JB Fisher","year":"2017","unstructured":"Fisher, J. B. et al. The cohesin subunit Rad21 is a negative regulator of hematopoietic self-renewal through epigenetic repression of Hoxa7 and Hoxa9. Leukemia 31, 712\u2013719 (2017).","journal-title":"Leukemia"},{"key":"1200_CR26","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1089\/scd.2015.0063","volume":"24","author":"M Fournier","year":"2015","unstructured":"Fournier, M., Lebert-Ghali, C. & Bijl, J. J. HOXA4 provides stronger engraftment potential to short-term repopulating cells than HOXB4. Stem Cells Dev. 24, 2413\u20132422 (2015).","journal-title":"Stem Cells Dev."},{"key":"1200_CR27","doi-asserted-by":"crossref","unstructured":"Tan, S., et al. Dysregulated expression of Hoxa1 isoforms in hematopoietic stem and progenitor cells causes myelodysplastic syndromes. bioRxiv. 2023:2023.2004.2024.538176.","DOI":"10.1101\/2023.04.24.538176"},{"key":"1200_CR28","doi-asserted-by":"publisher","first-page":"474A","DOI":"10.1182\/blood.V104.11.1706.1706","volume":"104","author":"SA Fabb","year":"2004","unstructured":"Fabb, S. A. et al. Novel roles for the homeobox gene, HoxA1, and its truncated form, HoxA1-T, in the regulation of hematopoietic stem cell self-renewal. Blood 104, 474A\u2013474A (2004).","journal-title":"Blood"},{"key":"1200_CR29","doi-asserted-by":"publisher","first-page":"S25","DOI":"10.1016\/j.exphem.2019.06.244","volume":"76","author":"L Purton","year":"2019","unstructured":"Purton, L. Key roles of hoxa1 in hscs and myelodysplastic syndromes. Exp. Hematol. 76, S25\u2013S25 (2019).","journal-title":"Exp. Hematol."},{"key":"1200_CR30","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1182\/blood.V118.21.2423.2423","volume":"118","author":"J Hendy","year":"2011","unstructured":"Hendy, J. et al. Deregulated Hoxa1 expression in murine bone marrow results in an MDS-like phenotype. Blood 118, 1041\u20131042 (2011).","journal-title":"Blood"},{"key":"1200_CR31","doi-asserted-by":"publisher","first-page":"3990","DOI":"10.1093\/nar\/gkr1240","volume":"40","author":"IJ Donaldson","year":"2012","unstructured":"Donaldson, I. J. et al. Genome-wide occupancy links Hoxa2 to Wnt-\u03b2-catenin signaling in mouse embryonic development. Nucleic Acids Res. 40, 3990\u20134001 (2012).","journal-title":"Nucleic Acids Res."},{"key":"1200_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2021.166928","volume":"433","author":"D Tang","year":"2021","unstructured":"Tang, D. et al. Pontin functions as a transcriptional co-activator for retinoic acid-induced HOX gene expression. J. Mol. Biol. 433, 166928 (2021).","journal-title":"J. Mol. Biol."},{"key":"1200_CR33","doi-asserted-by":"publisher","first-page":"9601","DOI":"10.1073\/pnas.90.20.9601","volume":"90","author":"JF Boylan","year":"1993","unstructured":"Boylan, J. F., Lohnes, D., Taneja, R., Chambon, P. & Gudas, L. J. Loss of retinoic acid receptor gamma function in F9 cells by gene disruption results in aberrant Hoxa-1 expression and differentiation upon retinoic acid treatment. Proc. Natl. Acad. Sci. USA 90, 9601\u20139605 (1993).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1200_CR34","doi-asserted-by":"crossref","unstructured":"Cooper, F. et al. Notch signalling influences cell fate decisions and HOX gene induction in axial progenitors. Development. 151 (2024).","DOI":"10.1242\/dev.202098"},{"key":"1200_CR35","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1242\/dev.128.6.993","volume":"128","author":"D Beuchle","year":"2001","unstructured":"Beuchle, D., Struhl, G. & M\u00fcller, J. Polycomb group proteins and heritable silencing of Drosophila Hox genes. Development 128, 993\u20131004 (2001).","journal-title":"Development"},{"key":"1200_CR36","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.stem.2007.05.019","volume":"1","author":"CD Jude","year":"2007","unstructured":"Jude, C. D. et al. Unique and independent roles for MLL in adult hematopoietic stem cells and progenitors. Cell Stem Cell 1, 324\u2013337 (2007).","journal-title":"Cell Stem Cell"},{"key":"1200_CR37","doi-asserted-by":"publisher","first-page":"7517","DOI":"10.1073\/pnas.0800090105","volume":"105","author":"FE Erfurth","year":"2008","unstructured":"Erfurth, F. E. et al. MLL protects CpG clusters from methylation within the Hoxa9 gene, maintaining transcript expression. Proc. Natl. Acad. Sci. USA 105, 7517\u20137522 (2008).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1200_CR38","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.cell.2007.02.009","volume":"128","author":"B Schuettengruber","year":"2007","unstructured":"Schuettengruber, B., Chourrout, D., Vervoort, M., Leblanc, B. & Cavalli, G. Genome regulation by polycomb and trithorax proteins. Cell 128, 735\u2013745 (2007).","journal-title":"Cell"},{"key":"1200_CR39","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1182\/blood-2007-04-085407","volume":"111","author":"VP Rawat","year":"2008","unstructured":"Rawat, V. P. et al. Overexpression of CDX2 perturbs HOX gene expression in murine progenitors depending on its N-terminal domain and is closely correlated with deregulated HOX gene expression in human acute myeloid leukemia. Blood 111, 309\u2013319 (2008).","journal-title":"Blood"},{"key":"1200_CR40","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1371\/journal.pone.0000047","volume":"1","author":"J Yan","year":"2006","unstructured":"Yan, J. et al. Cdx4 and menin co-regulate Hoxa9 expression in hematopoietic cells. PLoS One 1, e47 (2006).","journal-title":"PLoS One"},{"key":"1200_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.108758","volume":"34","author":"HS Jung","year":"2021","unstructured":"Jung, H. S. et al. SOX17 integrates HOXA and arterial programs in hemogenic endothelium to drive definitive lympho-myeloid hematopoiesis. Cell Rep. 34, 108758 (2021).","journal-title":"Cell Rep."},{"key":"1200_CR42","doi-asserted-by":"publisher","first-page":"2657","DOI":"10.1101\/gad.288324.116","volume":"30","author":"V Narendra","year":"2016","unstructured":"Narendra, V., Bulaji\u0107, M., Dekker, J., Mazzoni, E. O. & Reinberg, D. CTCF-mediated topological boundaries during development foster appropriate gene regulation. Genes Dev. 30, 2657\u20132662 (2016).","journal-title":"Genes Dev."},{"key":"1200_CR43","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1182\/blood-2017-11-814319","volume":"132","author":"H Luo","year":"2018","unstructured":"Luo, H. et al. CTCF boundary remodels chromatin domain and drives aberrant HOX gene transcription in acute myeloid leukemia. Blood 132, 837\u2013848 (2018).","journal-title":"Blood"},{"key":"1200_CR44","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1101\/gr.219386.116","volume":"27","author":"B De Kumar","year":"2017","unstructured":"De Kumar, B. et al. HOXA1 and TALE proteins display cross-regulatory interactions and form a combinatorial binding code on HOXA1 targets. Genome Res 27, 1501\u20131512 (2017).","journal-title":"Genome Res"},{"key":"1200_CR45","doi-asserted-by":"publisher","first-page":"3644","DOI":"10.1093\/emboj\/16.12.3644","volume":"16","author":"G Di Rocco","year":"1997","unstructured":"Di Rocco, G., Mavilio, F. & Zappavigna, V. Functional dissection of a transcriptionally active, target-specific Hox-Pbx complex. Embo J. 16, 3644\u20133654 (1997).","journal-title":"Embo J."},{"key":"1200_CR46","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/nature09819","volume":"472","author":"KC Wang","year":"2011","unstructured":"Wang, K. C. et al. A long noncoding RNA maintains active chromatin to coordinate homeotic gene expression. Nature 472, 120\u2013124 (2011).","journal-title":"Nature"},{"key":"1200_CR47","first-page":"1091","volume":"45","author":"XQ Wang","year":"2017","unstructured":"Wang, X. Q. & Dostie, J. Reciprocal regulation of chromatin state and architecture by HOTAIRM1 contributes to temporal collinear HOXA gene activation. Nucleic Acids Res. 45, 1091\u20131104 (2017).","journal-title":"Nucleic Acids Res."},{"key":"1200_CR48","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.1093\/nar\/gkv1315","volume":"44","author":"GY Liu","year":"2016","unstructured":"Liu, G. Y. et al. The long noncoding RNA Gm15055 represses Hoxa gene expression by recruiting PRC2 to the gene cluster. Nucleic Acids Res. 44, 2613\u20132627 (2016).","journal-title":"Nucleic Acids Res."},{"key":"1200_CR49","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1101\/gad.217018.113","volume":"27","author":"H Maamar","year":"2013","unstructured":"Maamar, H., Cabili, M. N., Rinn, J. & Raj, A. linc-HOXA1 is a noncoding RNA that represses Hoxa1 transcription in cis. Genes Dev. 27, 1260\u20131271 (2013).","journal-title":"Genes Dev."},{"key":"1200_CR50","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1084\/jem.20161595","volume":"214","author":"M Khalaj","year":"2017","unstructured":"Khalaj, M. et al. miR-99 regulates normal and malignant hematopoietic stem cell self-renewal. J. Exp. Med. 214, 2453\u20132470 (2017).","journal-title":"J. Exp. Med."},{"key":"1200_CR51","doi-asserted-by":"crossref","unstructured":"Xiong, Z. et al. Glutamylation of deubiquitinase BAP1 controls self-renewal of hematopoietic stem cells and hematopoiesis. J. Exp. Med. 217 (2020).","DOI":"10.1084\/jem.20190974"},{"key":"1200_CR52","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1084\/jem.20161087","volume":"214","author":"AV Guitart","year":"2017","unstructured":"Guitart, A. V. et al. Fumarate hydratase is a critical metabolic regulator of hematopoietic stem cell functions. J. Exp. Med. 214, 719\u2013735 (2017).","journal-title":"J. Exp. Med."},{"key":"1200_CR53","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1182\/blood-2015-02-626390","volume":"127","author":"C Lebert-Ghali","year":"2016","unstructured":"Lebert-Ghali, C. et al. Hoxa cluster genes determine the proliferative activity of adult mouse hematopoietic stem and progenitor cells. Blood 127, 87\u201390 (2016).","journal-title":"Blood"},{"key":"1200_CR54","doi-asserted-by":"publisher","first-page":"4732","DOI":"10.1182\/blood-2006-08-043356","volume":"109","author":"YL Hu","year":"2007","unstructured":"Hu, Y. L., Passegu\u00e9, E., Fong, S., Largman, C. & Lawrence, H. J. Evidence that the Pim1 kinase gene is a direct target of HOXA9. Blood 109, 4732\u20134738 (2007).","journal-title":"Blood"},{"key":"1200_CR55","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.18632\/oncotarget.1306","volume":"4","author":"G Brumatti","year":"2013","unstructured":"Brumatti, G. et al. HoxA9 regulated Bcl-2 expression mediates survival of myeloid progenitors and the severity of HoxA9-dependent leukemia. Oncotarget 4, 1933\u20131947 (2013).","journal-title":"Oncotarget"},{"key":"1200_CR56","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1182\/blood-2005-12-5014","volume":"108","author":"JL Hess","year":"2006","unstructured":"Hess, J. L. et al. c-Myb is an essential downstream target for homeobox-mediated transformation of hematopoietic cells. Blood 108, 297\u2013304 (2006).","journal-title":"Blood"},{"key":"1200_CR57","doi-asserted-by":"publisher","first-page":"3137","DOI":"10.1182\/bloodadvances.2018025866","volume":"2","author":"X Zhong","year":"2018","unstructured":"Zhong, X. et al. HoxA9 transforms murine myeloid cells by a feedback loop driving expression of key oncogenes and cell cycle control genes. Blood Adv. 2, 3137\u20133148 (2018).","journal-title":"Blood Adv."},{"key":"1200_CR58","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1038\/leu.2014.287","volume":"29","author":"J Steger","year":"2015","unstructured":"Steger, J., F\u00fcller, E., Garcia-Cuellar, M. P., Hetzner, K. & Slany, R. K. Insulin-like growth factor 1 is a direct HOXA9 target important for hematopoietic transformation. Leukemia 29, 901\u2013908 (2015).","journal-title":"Leukemia"},{"key":"1200_CR59","doi-asserted-by":"publisher","first-page":"19047","DOI":"10.1074\/jbc.M110.213983","volume":"286","author":"L Bei","year":"2011","unstructured":"Bei, L. et al. HoxA10 activates CDX4 transcription and Cdx4 activates HOXA10 transcription in myeloid cells. J. Biol. Chem. 286, 19047\u201319064 (2011).","journal-title":"J. Biol. Chem."},{"key":"1200_CR60","doi-asserted-by":"publisher","first-page":"3687","DOI":"10.1182\/blood-2006-10-054676","volume":"109","author":"M Magnusson","year":"2007","unstructured":"Magnusson, M. et al. HOXA10 is a critical regulator for hematopoietic stem cells and erythroid\/megakaryocyte development. Blood 109, 3687\u20133696 (2007).","journal-title":"Blood"},{"key":"1200_CR61","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.1101\/gad.817100","volume":"14","author":"VC Bromleigh","year":"2000","unstructured":"Bromleigh, V. C. & Freedman, L. P. p21 is a transcriptional target of HOXA10 in differentiating myelomonocytic cells. Genes Dev. 14, 2581\u20132586 (2000).","journal-title":"Genes Dev."},{"key":"1200_CR62","doi-asserted-by":"publisher","first-page":"20117","DOI":"10.1074\/jbc.M907915199","volume":"275","author":"EA Eklund","year":"2000","unstructured":"Eklund, E. A., Jalava, A. & Kakar, R. Tyrosine phosphorylation of HoxA10 decreases DNA binding and transcriptional repression during interferon gamma -induced differentiation of myeloid leukemia cell lines. J. Biol. Chem. 275, 20117\u201320126 (2000).","journal-title":"J. Biol. Chem."},{"key":"1200_CR63","doi-asserted-by":"publisher","first-page":"16846","DOI":"10.1074\/jbc.M609744200","volume":"282","author":"L Bei","year":"2007","unstructured":"Bei, L. et al. Identification of a HoxA10 activation domain necessary for transcription of the gene encoding beta3 integrin during myeloid differentiation. J. Biol. Chem. 282, 16846\u201316859 (2007).","journal-title":"J. Biol. Chem."},{"key":"1200_CR64","doi-asserted-by":"publisher","first-page":"12359","DOI":"10.1074\/jbc.M408138200","volume":"280","author":"L Bei","year":"2005","unstructured":"Bei, L., Lu, Y. & Eklund, E. A. HOXA9 activates transcription of the gene encoding gp91Phox during myeloid differentiation. J. Biol. Chem. 280, 12359\u201312370 (2005).","journal-title":"J. Biol. Chem."},{"key":"1200_CR65","doi-asserted-by":"publisher","first-page":"6572","DOI":"10.4049\/jimmunol.0904203","volume":"185","author":"K Gwin","year":"2010","unstructured":"Gwin, K., Frank, E., Bossou, A. & Medina, K. L. Hoxa9 regulates Flt3 in lymphohematopoietic progenitors. J. Immunol. 185, 6572\u20136583 (2010).","journal-title":"J. Immunol."},{"key":"1200_CR66","doi-asserted-by":"publisher","first-page":"5471","DOI":"10.1038\/onc.2013.175","volume":"32","author":"FJ Calero-Nieto","year":"2013","unstructured":"Calero-Nieto, F. J. et al. HOX-mediated LMO2 expression in embryonic mesoderm is recapitulated in acute leukaemias. Oncogene 32, 5471\u20135480 (2013).","journal-title":"Oncogene"},{"key":"1200_CR67","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.ccell.2018.08.018","volume":"34","author":"Y Sun","year":"2018","unstructured":"Sun, Y. et al. HOXA9 Reprograms the Enhancer Landscape to Promote Leukemogenesis. Cancer Cell 34, 643\u2013658.e645 (2018).","journal-title":"Cancer Cell"},{"key":"1200_CR68","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1182\/blood-2011-03-341081","volume":"119","author":"Y Huang","year":"2012","unstructured":"Huang, Y. et al. Identification and characterization of Hoxa9 binding sites in hematopoietic cells. Blood 119, 388\u2013398 (2012).","journal-title":"Blood"},{"key":"1200_CR69","doi-asserted-by":"publisher","first-page":"6737","DOI":"10.1093\/nar\/gkz482","volume":"47","author":"G Su","year":"2019","unstructured":"Su, G. et al. A distal enhancer maintaining Hoxa1 expression orchestrates retinoic acid-induced early ESCs differentiation. Nucleic Acids Res. 47, 6737\u20136752 (2019).","journal-title":"Nucleic Acids Res."},{"key":"1200_CR70","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13578-015-0020-3","volume":"5","author":"F Kocabas","year":"2015","unstructured":"Kocabas, F. et al. Hypoxic metabolism in human hematopoietic stem cells. Cell Biosci. 5, 39 (2015).","journal-title":"Cell Biosci."},{"key":"1200_CR71","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s40164-016-0053-2","volume":"5","author":"HG Wiktorin","year":"2015","unstructured":"Wiktorin, H. G., Nilsson, T., Jansson, A., Palmqvist, L. & Martner, A. Mutated NPM1 in combination with overexpression of Meis1 or Hoxa9 is not sufficient to induce acute myeloid leukemia. Exp. Hematol. Oncol. 5, 25 (2015).","journal-title":"Exp. Hematol. Oncol."},{"key":"1200_CR72","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/nature22370","volume":"545","author":"R Sugimura","year":"2017","unstructured":"Sugimura, R. et al. Haematopoietic stem and progenitor cells from human pluripotent stem cells. Nature 545, 432\u2013438 (2017).","journal-title":"Nature"},{"key":"1200_CR73","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1101\/gad.1111603","volume":"17","author":"PM Ayton","year":"2003","unstructured":"Ayton, P. M. & Cleary, M. L. Transformation of myeloid progenitors by MLL oncoproteins is dependent on Hoxa7 and Hoxa9. Genes Dev. 17, 2298\u20132307 (2003).","journal-title":"Genes Dev."},{"key":"1200_CR74","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jare.2019.05.006","volume":"20","author":"\u00c1 Nagy","year":"2019","unstructured":"Nagy, \u00c1 et al. Elevated HOX gene expression in acute myeloid leukemia is associated with NPM1 mutations and poor survival. J. Adv. Res 20, 105\u2013116 (2019).","journal-title":"J. Adv. Res"},{"key":"1200_CR75","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1038\/ncb1608","volume":"9","author":"GG Wang","year":"2007","unstructured":"Wang, G. G., Cai, L., Pasillas, M. P. & Kamps, M. P. NUP98-NSD1 links H3K36 methylation to Hox-A gene activation and leukaemogenesis. Nat. Cell Biol. 9, 804\u2013812 (2007).","journal-title":"Nat. Cell Biol."},{"key":"1200_CR76","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10924","volume":"7","author":"J Koya","year":"2016","unstructured":"Koya, J. et al. DNMT3A R882 mutants interact with polycomb proteins to block haematopoietic stem and leukaemic cell differentiation. Nat. Commun. 7, 10924 (2016).","journal-title":"Nat. Commun."},{"key":"1200_CR77","doi-asserted-by":"publisher","first-page":"2877","DOI":"10.1182\/blood-2013-03-491571","volume":"122","author":"A Chaturvedi","year":"2013","unstructured":"Chaturvedi, A. et al. Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML. Blood 122, 2877\u20132887 (2013).","journal-title":"Blood"},{"key":"1200_CR78","first-page":"268","volume":"15","author":"Xiuhong Jia","year":"2013","unstructured":"Jia, X. iuhong, Jianchang Li, L. Z. & Wang, C. uicui Expression and clinical significance of homeobox gene HOXA9 in childhood acute leukemia. Chin. J. Contemp. Pediatrics 15, 268\u2013272 (2013).","journal-title":"Chin. J. Contemp. Pediatrics"},{"key":"1200_CR79","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1038\/leu.2008.198","volume":"22","author":"M Andreeff","year":"2008","unstructured":"Andreeff, M. et al. HOX expression patterns identify a common signature for favorable AML. Leukemia 22, 2041\u20132047 (2008).","journal-title":"Leukemia"},{"key":"1200_CR80","doi-asserted-by":"publisher","first-page":"5639","DOI":"10.1128\/MCB.24.13.5639-5649.2004","volume":"24","author":"A Yokoyama","year":"2004","unstructured":"Yokoyama, A. et al. Leukemia proto-oncoprotein MLL forms a SET1-like histone methyltransferase complex with menin to regulate Hox gene expression. Mol. Cell Biol. 24, 5639\u20135649 (2004).","journal-title":"Mol. Cell Biol."},{"key":"1200_CR81","doi-asserted-by":"publisher","first-page":"10632","DOI":"10.1073\/pnas.95.18.10632","volume":"95","author":"BD Yu","year":"1998","unstructured":"Yu, B. D., Hanson, R. D., Hess, J. L., Horning, S. E. & Korsmeyer, S. J. MLL, a mammalian trithorax-group gene, functions as a transcriptional maintenance factor in morphogenesis. Proc. Natl. Acad. Sci. USA 95, 10632\u201310636 (1998).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1200_CR82","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1073\/pnas.0510347103","volume":"103","author":"YX Chen","year":"2006","unstructured":"Chen, Y. X. et al. The tumor suppressor menin regulates hematopoiesis and myeloid transformation by influencing Hox gene expression. Proc. Natl. Acad. Sci. USA 103, 1018\u20131023 (2006).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1200_CR83","doi-asserted-by":"publisher","first-page":"4195","DOI":"10.1172\/JCI62891","volume":"123","author":"A Li","year":"2013","unstructured":"Li, A. et al. A SALL4\/MLL\/HOXA9 pathway in murine and human myeloid leukemogenesis. J. Clin. Invest 123, 4195\u20134207 (2013).","journal-title":"J. Clin. Invest"},{"key":"1200_CR84","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.cell.2005.09.025","volume":"123","author":"A Yokoyama","year":"2005","unstructured":"Yokoyama, A. et al. The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis. Cell 123, 207\u2013218 (2005).","journal-title":"Cell"},{"key":"1200_CR85","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ccr.2008.05.003","volume":"14","author":"A Yokoyama","year":"2008","unstructured":"Yokoyama, A. & Cleary, M. L. Menin critically links MLL proteins with LEDGF on cancer-associated target genes. Cancer Cell 14, 36\u201346 (2008).","journal-title":"Cancer Cell"},{"key":"1200_CR86","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1038\/nature10806","volume":"482","author":"J Huang","year":"2012","unstructured":"Huang, J. et al. The same pocket in menin binds both MLL and JUND but has opposite effects on transcription. Nature 482, 542\u2013546 (2012).","journal-title":"Nature"},{"key":"1200_CR87","doi-asserted-by":"publisher","first-page":"5139","DOI":"10.1158\/0008-5472.CAN-13-3602","volume":"74","author":"K Cerm\u00e1kov\u00e1","year":"2014","unstructured":"Cerm\u00e1kov\u00e1, K. et al. Validation and structural characterization of the LEDGF\/p75-MLL interface as a new target for the treatment of MLL-dependent leukemia. Cancer Res 74, 5139\u20135151 (2014).","journal-title":"Cancer Res"},{"key":"1200_CR88","first-page":"95","volume":"131","author":"S El Ashkar","year":"2018","unstructured":"El Ashkar, S. et al. LEDGF\/p75 is dispensable for hematopoiesis but essential for MLL-rearranged leukemogenesis. Blood 131, 95\u2013107 (2018).","journal-title":"Blood"},{"key":"1200_CR89","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1172\/JCI38030","volume":"120","author":"S Jin","year":"2010","unstructured":"Jin, S. et al. c-Myb binds MLL through menin in human leukemia cells and is an important driver of MLL-associated leukemogenesis. J. Clin. Investig. 120, 593\u2013606 (2010).","journal-title":"J. Clin. Investig."},{"key":"1200_CR90","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.celrep.2014.09.002","volume":"9","author":"P Pascual-Garcia","year":"2014","unstructured":"Pascual-Garcia, P., Jeong, J. & Capelson, M. Nucleoporin Nup98 associates with Trx\/MLL and NSL histone-modifying complexes and regulates Hox gene expression. Cell Rep. 9, 433\u2013442 (2014).","journal-title":"Cell Rep."},{"key":"1200_CR91","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.112884","volume":"42","author":"M Oka","year":"2023","unstructured":"Oka, M. et al. Phase-separated nuclear bodies of nucleoporin fusions promote condensation of MLL1\/CRM1 and rearrangement of 3D genome structure. Cell Rep. 42, 112884 (2023).","journal-title":"Cell Rep."},{"key":"1200_CR92","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1128\/MCB.19.1.764","volume":"19","author":"LH Kasper","year":"1999","unstructured":"Kasper, L. H. et al. CREB binding protein interacts with nucleoporin-specific FG repeats that activate transcription and mediate NUP98-HOXA9 oncogenicity. Mol. Cell Biol. 19, 764\u2013776 (1999).","journal-title":"Mol. Cell Biol."},{"key":"1200_CR93","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.09540","volume":"5","author":"M Oka","year":"2016","unstructured":"Oka, M. et al. Chromatin-prebound Crm1 recruits Nup98-HoxA9 fusion to induce aberrant expression of Hox cluster genes. Elife 5, e09540 (2016).","journal-title":"Elife"},{"key":"1200_CR94","doi-asserted-by":"publisher","first-page":"38989","DOI":"10.1074\/jbc.M111.297952","volume":"286","author":"NJ Sarma","year":"2011","unstructured":"Sarma, N. J. & Yaseen, N. R. Amino-terminal enhancer of split (AES) interacts with the oncoprotein NUP98-HOXA9 and enhances its transforming ability. J. Biol. Chem. 286, 38989\u201339001 (2011).","journal-title":"J. Biol. Chem."},{"key":"1200_CR95","doi-asserted-by":"publisher","first-page":"e67032","DOI":"10.1371\/journal.pone.0067032","volume":"8","author":"NJ Sarma","year":"2013","unstructured":"Sarma, N. J. & Yaseen, N. R. Dynein Light Chain 1 (DYNLT1) Interacts with Normal and Oncogenic Nucleoporins. PLoS One 8, e67032 (2013).","journal-title":"PLoS One"},{"key":"1200_CR96","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1038\/sj.emboj.7601037","volume":"25","author":"N Wang","year":"2006","unstructured":"Wang, N. et al. TGFbeta\/BMP inhibits the bone marrow transformation capability of Hoxa9 by repressing its DNA-binding ability. Embo J. 25, 1469\u20131480 (2006).","journal-title":"Embo J."},{"key":"1200_CR97","doi-asserted-by":"publisher","first-page":"5918","DOI":"10.1182\/blood-2010-08-301879","volume":"117","author":"R Qu\u00e9r\u00e9","year":"2011","unstructured":"Qu\u00e9r\u00e9, R. et al. Smad4 binds Hoxa9 in the cytoplasm and protects primitive hematopoietic cells against nuclear activation by Hoxa9 and leukemia transformation. Blood 117, 5918\u20135930 (2011).","journal-title":"Blood"},{"key":"1200_CR98","doi-asserted-by":"publisher","first-page":"6281","DOI":"10.1093\/nar\/gkab473","volume":"49","author":"Y Fang","year":"2021","unstructured":"Fang, Y. et al. The H3K36me2 methyltransferase NSD1 modulates H3K27ac at active enhancers to safeguard gene expression. Nucleic Acids Res. 49, 6281\u20136295 (2021).","journal-title":"Nucleic Acids Res."},{"key":"1200_CR99","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1111\/gtc.12886","volume":"26","author":"S Cigdem","year":"2021","unstructured":"Cigdem, S., Saito, S., Nishikata, D., Nagata, K. & Okuwaki, M. SET-NUP214 and MLL cooperatively regulate the promoter activity of the HoxA10 gene. Genes Cells 26, 830\u2013837 (2021).","journal-title":"Genes Cells"},{"key":"1200_CR100","doi-asserted-by":"crossref","unstructured":"Ikeda, D. et al. Molecular classification and overcoming therapy resistance for acute myeloid leukemia with adverse genetic factors. Int. J. Mol. Sci. 23 (2022).","DOI":"10.3390\/ijms23115950"},{"key":"1200_CR101","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1038\/s41375-025-02593-8","volume":"39","author":"F Kaya","year":"2025","unstructured":"Kaya, F. et al. DEK::NUP214 acts as an XPO1-dependent transcriptional activator of essential leukemia genes. Leukemia 39, 1526\u20131531 (2025).","journal-title":"Leukemia"},{"key":"1200_CR102","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.ccr.2009.12.034","volume":"17","author":"AT Thiel","year":"2010","unstructured":"Thiel, A. T. et al. MLL-AF9-induced leukemogenesis requires coexpression of the wild-type MLL allele. Cancer Cell 17, 148\u2013159 (2010).","journal-title":"Cancer Cell"},{"key":"1200_CR103","doi-asserted-by":"publisher","first-page":"7956","DOI":"10.1073\/pnas.1103154108","volume":"108","author":"K Orlovsky","year":"2011","unstructured":"Orlovsky, K. et al. Down-regulation of homeobox genes MEIS1 and HOXA in MLL-rearranged acute leukemia impairs engraftment and reduces proliferation. Proc. Natl. Acad. Sci. USA 108, 7956\u20137961 (2011).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1200_CR104","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1101\/gad.311639.118","volume":"32","author":"H Zhang","year":"2018","unstructured":"Zhang, H. et al. Structural and functional analysis of the DOT1L-AF10 complex reveals mechanistic insights into MLL-AF10-associated leukemogenesis. Genes Dev. 32, 341\u2013346 (2018).","journal-title":"Genes Dev."},{"key":"1200_CR105","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/onc.2017.337","volume":"37","author":"J Serio","year":"2018","unstructured":"Serio, J. et al. The PAF complex regulation of Prmt5 facilitates the progression and maintenance of MLL fusion leukemia. Oncogene 37, 450\u2013460 (2018).","journal-title":"Oncogene"},{"key":"1200_CR106","doi-asserted-by":"crossref","unstructured":"Fioretti, T. et al. Nuclear FGFR2 interacts with the MLL-AF4 oncogenic chimera and positively regulates HOXA9 gene expression in t(4;11) leukemia cells. Int. J. Mol. Sci. 22 (2021).","DOI":"10.3390\/ijms22094623"},{"key":"1200_CR107","doi-asserted-by":"publisher","first-page":"3901","DOI":"10.1073\/pnas.1301045110","volume":"110","author":"E Wang","year":"2013","unstructured":"Wang, E. et al. Histone H2B ubiquitin ligase RNF20 is required for MLL-rearranged leukemia. Proc. Natl. Acad. Sci. USA 110, 3901\u20133906 (2013).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1200_CR108","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1038\/leu.2013.384","volume":"28","author":"J Zhou","year":"2014","unstructured":"Zhou, J. et al. PU.1 is essential for MLL leukemia partially via crosstalk with the MEIS\/HOX pathway. Leukemia 28, 1436\u20131448 (2014).","journal-title":"Leukemia"},{"key":"1200_CR109","doi-asserted-by":"publisher","first-page":"2707","DOI":"10.1172\/JCI25546","volume":"116","author":"AM Dorrance","year":"2006","unstructured":"Dorrance, A. M. et al. Mll partial tandem duplication induces aberrant Hox expression in vivo via specific epigenetic alterations. J. Clin. Investig. 116, 2707\u20132716 (2006).","journal-title":"J. Clin. Investig."},{"key":"1200_CR110","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.ccell.2018.08.005","volume":"34","author":"L Brunetti","year":"2018","unstructured":"Brunetti, L. et al. Mutant NPM1 maintains the leukemic state through HOX expression. Cancer Cell 34, 499\u2013512.e499 (2018).","journal-title":"Cancer Cell"},{"key":"1200_CR111","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01004-y","volume":"14","author":"I Khan","year":"2024","unstructured":"Khan, I., Amin, M. A., Eklund, E. A. & Gartel, A. L. Regulation of HOX gene expression in AML. Blood Cancer J. 14, 42 (2024).","journal-title":"Blood Cancer J."},{"key":"1200_CR112","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/s41375-020-0856-3","volume":"35","author":"R Ghasemi","year":"2021","unstructured":"Ghasemi, R., Struthers, H., Wilson, E. R. & Spencer, D. H. Contribution of CTCF binding to transcriptional activity at the HOXA locus in NPM1-mutant AML cells. Leukemia 35, 404\u2013416 (2021).","journal-title":"Leukemia"},{"key":"1200_CR113","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41375-024-02438-w","volume":"39","author":"Y Shimosato","year":"2025","unstructured":"Shimosato, Y. et al. NPM1-fusion proteins promote myeloid leukemogenesis through XPO1-dependent HOX activation. Leukemia 39, 75\u201386 (2025).","journal-title":"Leukemia"},{"key":"1200_CR114","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1182\/blood.2023021359","volume":"143","author":"JM Barajas","year":"2024","unstructured":"Barajas, J. M. et al. Acute myeloid leukemias with UBTF tandem duplications are sensitive to menin inhibitors. Blood 143, 619\u2013630 (2024).","journal-title":"Blood"},{"key":"1200_CR115","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1182\/blood.2023023041","volume":"143","author":"KM Bernt","year":"2024","unstructured":"Bernt, K. M. Menin dependence: UBTF-ITD AML joins the club. Blood 143, 567\u2013569 (2024).","journal-title":"Blood"},{"key":"1200_CR116","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.1056\/NEJMc2404110","volume":"390","author":"IS Tiong","year":"2024","unstructured":"Tiong, I. S., Ritchie, D. S. & Blombery, P. Response and Resistance to Menin Inhibitor in UBTF-Tandem Duplication AML. N. Engl. J. Med. 390, 2323\u20132325 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1200_CR117","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1038\/s41375-021-01146-z","volume":"35","author":"C Libbrecht","year":"2021","unstructured":"Libbrecht, C. et al. Menin is necessary for long term maintenance of meningioma-1 driven leukemia. Leukemia 35, 1405\u20131417 (2021).","journal-title":"Leukemia"},{"key":"1200_CR118","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1182\/blood.2019003701","volume":"136","author":"S Ottema","year":"2020","unstructured":"Ottema, S. et al. Atypical 3q26\/MECOM rearrangements genocopy inv(3)\/t(3;3) in acute myeloid leukemia. Blood 136, 224\u2013234 (2020).","journal-title":"Blood"},{"key":"1200_CR119","doi-asserted-by":"publisher","first-page":"3998","DOI":"10.1182\/blood-2006-08-041202","volume":"109","author":"G Jin","year":"2007","unstructured":"Jin, G. et al. Trib1 and Evi1 cooperate with Hoxa and Meis1 in myeloid leukemogenesis. Blood 109, 3998\u20134005 (2007).","journal-title":"Blood"},{"key":"1200_CR120","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1182\/blood.V101.4.1558","volume":"101","author":"A Thompson","year":"2003","unstructured":"Thompson, A. et al. Global down-regulation of HOX gene expression in PML-RARalpha + acute promyelocytic leukemia identified by small-array real-time PCR. Blood 101, 1558\u20131565 (2003).","journal-title":"Blood"},{"key":"1200_CR121","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1038\/sj.leu.2404376","volume":"20","author":"I Casorelli","year":"2006","unstructured":"Casorelli, I. et al. Identification of a molecular signature for leukemic promyelocytes and their normal counterparts: Focus on DNA repair genes. Leukemia 20, 1978\u20131988 (2006).","journal-title":"Leukemia"},{"key":"1200_CR122","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1182\/blood-2008-05-158139","volume":"113","author":"A Saumet","year":"2009","unstructured":"Saumet, A. et al. Transcriptional repression of microRNA genes by PML-RARA increases expression of key cancer proteins in acute promyelocytic leukemia. Blood 113, 412\u2013421 (2009).","journal-title":"Blood"},{"key":"1200_CR123","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1080\/15592294.2017.1413517","volume":"13","author":"K Rejlova","year":"2018","unstructured":"Rejlova, K. et al. Low HOX gene expression in PML-RAR\u03b1-positive leukemia results from suppressed histone demethylation. Epigenetics 13, 73\u201384 (2018).","journal-title":"Epigenetics"},{"key":"1200_CR124","doi-asserted-by":"publisher","first-page":"4758","DOI":"10.1182\/blood-2012-06-435792","volume":"121","author":"AE Conway","year":"2013","unstructured":"Conway, A. E., Scotland, P. B., Lavau, C. P. & Wechsler, D. S. A CALM-derived nuclear export signal is essential for CALM-AF10-mediated leukemogenesis. Blood 121, 4758\u20134768 (2013).","journal-title":"Blood"},{"key":"1200_CR125","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/leu.2014.221","volume":"29","author":"AE Conway","year":"2015","unstructured":"Conway, A. E., Haldeman, J. M., Wechsler, D. S. & Lavau, C. P. A critical role for CRM1 in regulating HOXA gene transcription in CALM-AF10 leukemias. Leukemia 29, 423\u2013432 (2015).","journal-title":"Leukemia"},{"key":"1200_CR126","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1038\/ncb1464","volume":"8","author":"Y Okada","year":"2006","unstructured":"Okada, Y. et al. Leukaemic transformation by CALM-AF10 involves upregulation of Hoxa5 by hDOT1L. Nat. Cell Biol. 8, 1017\u20131024 (2006).","journal-title":"Nat. Cell Biol."},{"key":"1200_CR127","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1182\/blood-2024-194827","volume":"144","author":"JF Zeidner","year":"2024","unstructured":"Zeidner, J. F. et al. Phase 1 results: first-in-human phase 1\/2 study of the menin-MLL inhibitor enzomenib (DSP-5336) in patients with relapsed or refractory acute leukemia. Blood 144, 213\u2013213 (2024).","journal-title":"Blood"},{"key":"1200_CR128","doi-asserted-by":"publisher","DOI":"10.1038\/oncsis.2014.49","volume":"3","author":"L Bei","year":"2014","unstructured":"Bei, L. et al. Regulation of CDX4 gene transcription by HoxA9, HoxA10, the Mll-Ell oncogene and Shp2 during leukemogenesis. Oncogenesis 3, e135 (2014).","journal-title":"Oncogenesis"},{"key":"1200_CR129","doi-asserted-by":"publisher","first-page":"7275","DOI":"10.1158\/0008-5472.CAN-06-2369","volume":"67","author":"C Caslini","year":"2007","unstructured":"Caslini, C. et al. Interaction of MLL amino terminal sequences with menin is required for transformation. Cancer Res. 67, 7275\u20137283 (2007).","journal-title":"Cancer Res."},{"key":"1200_CR130","doi-asserted-by":"publisher","first-page":"40690","DOI":"10.1074\/jbc.M110.172783","volume":"285","author":"J Grembecka","year":"2010","unstructured":"Grembecka, J., Belcher, A. M., Hartley, T. & Cierpicki, T. Molecular basis of the mixed lineage leukemia-menin interaction: implications for targeting mixed lineage leukemias. J. Biol. Chem. 285, 40690\u201340698 (2010).","journal-title":"J. Biol. Chem."},{"key":"1200_CR131","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/nchembio.773","volume":"8","author":"J Grembecka","year":"2012","unstructured":"Grembecka, J. et al. Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia. Nat. Chem. Biol. 8, 277\u2013284 (2012).","journal-title":"Nat. Chem. Biol."},{"key":"1200_CR132","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1021\/jm3015298","volume":"56","author":"H Zhou","year":"2013","unstructured":"Zhou, H. et al. Structure-based design of high-affinity macrocyclic peptidomimetics to block the menin-mixed lineage leukemia 1 (MLL1) protein-protein interaction. J. Med. Chem. 56, 1113\u20131123 (2013).","journal-title":"J. Med. Chem."},{"key":"1200_CR133","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.ccell.2015.02.016","volume":"27","author":"D Borkin","year":"2015","unstructured":"Borkin, D. et al. Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in vivo. Cancer Cell 27, 589\u2013602 (2015).","journal-title":"Cancer Cell"},{"key":"1200_CR134","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1038\/leu.2015.144","volume":"30","author":"S He","year":"2016","unstructured":"He, S. et al. Menin-MLL inhibitors block oncogenic transformation by MLL-fusion proteins in a fusion partner-independent manner. Leukemia 30, 508\u2013513 (2016).","journal-title":"Leukemia"},{"key":"1200_CR135","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1021\/acs.jmedchem.5b01305","volume":"59","author":"D Borkin","year":"2016","unstructured":"Borkin, D. et al. Property Focused Structure-Based Optimization of Small Molecule Inhibitors of the Protein-Protein Interaction between Menin and Mixed Lineage Leukemia (MLL). J. Med. Chem. 59, 892\u2013913 (2016).","journal-title":"J. Med. Chem."},{"key":"1200_CR136","doi-asserted-by":"publisher","first-page":"5788","DOI":"10.1039\/C6CC01079B","volume":"52","author":"HJ Zhong","year":"2016","unstructured":"Zhong, H. J. et al. Structure-based screening and optimization of cytisine derivatives as inhibitors of the menin-MLL interaction. Chem. Commun. 52, 5788\u20135791 (2016).","journal-title":"Chem. Commun."},{"key":"1200_CR137","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1021\/jm401868d","volume":"57","author":"S He","year":"2014","unstructured":"He, S. et al. High-affinity small-molecule inhibitors of the menin-mixed lineage leukemia (MLL) interaction closely mimic a natural protein-protein interaction. J. Med. Chem. 57, 1543\u20131556 (2014).","journal-title":"J. Med. Chem."},{"key":"1200_CR138","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1002\/anie.201711828","volume":"57","author":"S Xu","year":"2018","unstructured":"Xu, S. et al. Design of the first-in-class, highly potent irreversible inhibitor targeting the menin-MLL protein-protein interaction. Angew. Chem. Int. Ed. Engl. 57, 1601\u20131605 (2018).","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"1200_CR139","doi-asserted-by":"publisher","first-page":"4832","DOI":"10.1021\/acs.jmedchem.8b00071","volume":"61","author":"D Borkin","year":"2018","unstructured":"Borkin, D. et al. Complexity of blocking bivalent protein-protein interactions: development of a highly potent inhibitor of the menin-mixed-lineage leukemia interaction. J. Med. Chem. 61, 4832\u20134850 (2018).","journal-title":"J. Med. Chem."},{"key":"1200_CR140","doi-asserted-by":"publisher","first-page":"6015","DOI":"10.1021\/acs.jmedchem.9b00021","volume":"62","author":"A Aguilar","year":"2019","unstructured":"Aguilar, A. et al. Structure-based discovery of M-89 as a highly potent inhibitor of the menin-mixed lineage leukemia (menin-MLL) protein-protein interaction. J. Med. Chem. 62, 6015\u20136034 (2019).","journal-title":"J. Med. Chem."},{"key":"1200_CR141","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.ccell.2019.11.001","volume":"36","author":"AV Krivtsov","year":"2019","unstructured":"Krivtsov, A. V. et al. A Menin-MLL inhibitor induces specific chromatin changes and eradicates disease in models of MLL-rearranged leukemia. Cancer Cell 36, 660\u2013673.e611 (2019).","journal-title":"Cancer Cell"},{"key":"1200_CR142","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1158\/2159-8290.CD-16-0237","volume":"6","author":"MW K\u00fchn","year":"2016","unstructured":"K\u00fchn, M. W. et al. Targeting chromatin regulators inhibits leukemogenic gene expression in NPM1 mutant leukemia. Cancer Discov. 6, 1166\u20131181 (2016).","journal-title":"Cancer Discov."},{"key":"1200_CR143","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1038\/s41375-019-0382-3","volume":"33","author":"L Schmidt","year":"2019","unstructured":"Schmidt, L. et al. CEBPA-mutated leukemia is sensitive to genetic and pharmacological targeting of the MLL1 complex. Leukemia 33, 1608\u20131619 (2019).","journal-title":"Leukemia"},{"key":"1200_CR144","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1182\/blood.2021012806","volume":"139","author":"EB Heikamp","year":"2022","unstructured":"Heikamp, E. B. et al. The menin-MLL1 interaction is a molecular dependency in NUP98-rearranged AML. Blood 139, 894\u2013906 (2022).","journal-title":"Blood"},{"key":"1200_CR145","doi-asserted-by":"crossref","unstructured":"Brzezinka, K. et al. Characterization of the Menin-MLL interaction as therapeutic cancer target. Cancers. 12 (2020).","DOI":"10.3390\/cancers12010201"},{"key":"1200_CR146","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1126\/science.aax5863","volume":"367","author":"HJ Uckelmann","year":"2020","unstructured":"Uckelmann, H. J. et al. Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia. Science 367, 586\u2013590 (2020).","journal-title":"Science"},{"key":"1200_CR147","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1172\/JCI129126","volume":"130","author":"S Klossowski","year":"2020","unstructured":"Klossowski, S. et al. Menin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models of leukemia. J. Clin. Investig. 130, 981\u2013997 (2020).","journal-title":"J. Clin. Investig."},{"key":"1200_CR148","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.ccell.2020.02.011","volume":"37","author":"MC Gundry","year":"2020","unstructured":"Gundry, M. C., Goodell, M. A. & Brunetti, L. It\u2019s All About MEis: Menin-MLL inhibition eradicates NPM1-mutated and MLL-rearranged acute leukemias in mice. Cancer Cell 37, 267\u2013269 (2020).","journal-title":"Cancer Cell"},{"key":"1200_CR149","doi-asserted-by":"publisher","first-page":"4997","DOI":"10.1021\/acs.jmedchem.0c00547","volume":"63","author":"S Xu","year":"2020","unstructured":"Xu, S. et al. Discovery of M-808 as a highly potent, covalent, small-molecule inhibitor of the menin-MLL interaction with strong in vivo antitumor activity. J. Med. Chem. 63, 4997\u20135010 (2020).","journal-title":"J. Med. Chem."},{"key":"1200_CR150","doi-asserted-by":"publisher","first-page":"10333","DOI":"10.1021\/acs.jmedchem.1c00789","volume":"64","author":"M Zhang","year":"2021","unstructured":"Zhang, M. et al. Discovery of M-1121 as an Orally Active Covalent Inhibitor of Menin-MLL Interaction Capable of Achieving Complete and Long-Lasting Tumor Regression. J. Med. Chem. 64, 10333\u201310349 (2021).","journal-title":"J. Med. Chem."},{"key":"1200_CR151","doi-asserted-by":"publisher","first-page":"2442","DOI":"10.1182\/blood.2020005037","volume":"136","author":"MM Dzama","year":"2020","unstructured":"Dzama, M. M. et al. Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition. Blood 136, 2442\u20132456 (2020).","journal-title":"Blood"},{"key":"1200_CR152","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1182\/blood.2020007671","volume":"136","author":"AE Perl","year":"2020","unstructured":"Perl, A. E. MLL-menin and FLT3 inhibitors team up for AML. Blood 136, 2369\u20132370 (2020).","journal-title":"Blood"},{"key":"1200_CR153","doi-asserted-by":"publisher","first-page":"2958","DOI":"10.1182\/blood.2020006575","volume":"136","author":"H Miao","year":"2020","unstructured":"Miao, H. et al. Combinatorial treatment with menin and FLT3 inhibitors induces complete remission in AML models with activating FLT3 mutations. Blood 136, 2958\u20132963 (2020).","journal-title":"Blood"},{"key":"1200_CR154","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1182\/blood.2021011917","volume":"138","author":"BZ Carter","year":"2021","unstructured":"Carter, B. Z. et al. Menin inhibition decreases Bcl-2 and synergizes with venetoclax in NPM1\/FLT3-mutated AML. Blood 138, 1637\u20131641 (2021).","journal-title":"Blood"},{"key":"1200_CR155","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.3324\/haematol.2022.282160","volume":"108","author":"J Rausch","year":"2023","unstructured":"Rausch, J. et al. Menin inhibitor ziftomenib (KO-539) synergizes with drugs targeting chromatin regulation or apoptosis and sensitizes acute myeloid leukemia with MLL rearrangement or NPM1 mutation to venetoclax. Haematologica 108, 2837\u20132843 (2023).","journal-title":"Haematologica"},{"key":"1200_CR156","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00603-3","volume":"12","author":"W Fiskus","year":"2022","unstructured":"Fiskus, W. et al. Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c). Blood Cancer J. 12, 5 (2022).","journal-title":"Blood Cancer J."},{"key":"1200_CR157","doi-asserted-by":"publisher","first-page":"2729","DOI":"10.1038\/s41375-022-01707-w","volume":"36","author":"W Fiskus","year":"2022","unstructured":"Fiskus, W. et al. Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1. Leukemia 36, 2729\u20132733 (2022).","journal-title":"Leukemia"},{"key":"1200_CR158","doi-asserted-by":"publisher","first-page":"e935","DOI":"10.1097\/HS9.0000000000000935","volume":"7","author":"M Rasouli","year":"2023","unstructured":"Rasouli, M. et al. The MLL-menin interaction is a therapeutic vulnerability in NUP98-rearranged AML. Hemasphere 7, e935 (2023).","journal-title":"Hemasphere"},{"key":"1200_CR159","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s13045-019-0749-y","volume":"12","author":"K Brzezinka","year":"2019","unstructured":"Brzezinka, K. et al. Functional diversity of inhibitors tackling the differentiation blockage of MLL-rearranged leukemia. J. Hematol. Oncol. 12, 66 (2019).","journal-title":"J. Hematol. Oncol."},{"key":"1200_CR160","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-019-0723-0","volume":"11","author":"J Ye","year":"2019","unstructured":"Ye, J. et al. Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair. Clin. Epigenetics 11, 137 (2019).","journal-title":"Clin. Epigenetics"},{"key":"1200_CR161","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1158\/2159-8290.CD-22-0416","volume":"13","author":"YM Soto-Feliciano","year":"2023","unstructured":"Soto-Feliciano, Y. M. et al. A molecular switch between mammalian MLL complexes dictates response to menin-MLL inhibition. Cancer Discov. 13, 146\u2013169 (2023).","journal-title":"Cancer Discov."},{"key":"1200_CR162","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00826-6","volume":"13","author":"W Fiskus","year":"2023","unstructured":"Fiskus, W. et al. Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1. Blood Cancer J. 13, 53 (2023).","journal-title":"Blood Cancer J."},{"key":"1200_CR163","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1182\/blood.2023022480","volume":"144","author":"MC Kwon","year":"2024","unstructured":"Kwon, M. C. et al. Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in KMT2A- and NPM1-altered leukemias. Blood 144, 1206\u20131220 (2024).","journal-title":"Blood"},{"key":"1200_CR164","first-page":"7","volume":"24","author":"A Mullard","year":"2025","unstructured":"Mullard, A. FDA approves first menin inhibitor, for acute leukaemia. Nat. Rev. Drug Discov. 24, 7 (2025).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1200_CR165","unstructured":"FDA approves revumenib for relapsed or refractory acute myeloid leukemia with a susceptible NPM1 mutation [EB\/OL] 2025, https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-revumenib-relapsed-or-refractory-acute-myeloid-leukemia-susceptible-npm1-mutation."},{"key":"1200_CR166","unstructured":"Arellano, M. L. et al. Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study. Blood. (2025)."},{"key":"1200_CR167","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1200\/JCO.24.00826","volume":"43","author":"GC Issa","year":"2025","unstructured":"Issa, G. C. et al. Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101). J. Clin. Oncol. 43, 75\u201384 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1200_CR168","unstructured":"Ghayas Issa B. C. et al. REVUMENIB ACTIVITY IN PATIENTS WITH ACUTE LEUKEMIA WITH NUP98R: RESULTS FROM THE AUGMENT-101 PHASE 1 STUDY [EB\/OL] 2025, https:\/\/library.ehaweb.org\/eha\/2025\/eha2025-congress\/4160577\/ghayas.issa.revumenib.activity.in.patients.with.acute.leukemia.with.nup98r.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3DRevumenib."},{"key":"1200_CR169","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1182\/blood-2024-204375","volume":"144","author":"GC Issa","year":"2024","unstructured":"Issa, G. C. et al. Phase I\/II Study of the All-Oral Combination of Revumenib (SNDX-5613) with Decitabine\/Cedazuridine (ASTX727) and Venetoclax (SAVE) in R\/R AML. Blood 144, 216\u2013216 (2024).","journal-title":"Blood"},{"key":"1200_CR170","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1200\/JCO-25-00914","volume":"43","author":"JF Zeidner","year":"2025","unstructured":"Zeidner, J. F. et al. Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML. J. Clin. Oncol. 43, 2606\u20132615 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1200_CR171","doi-asserted-by":"crossref","unstructured":"Erba, H. P. et al. Update on a Phase 1\/2 First-in-Human Study of the Menin-KMT2A (MLL) Inhibitor Ziftomenib (KO-539) in Patients with Relapsed or Refractory Acute Myeloid Leukemia. Blood. 140 (2022).","DOI":"10.1182\/blood-2022-167412"},{"key":"1200_CR172","unstructured":"Wang, E. S. et al. Ziftomenib in Relapsed or Refractory NPM1-Mutated AML. J. Clin. Oncol. Jco2501694 (2025)."},{"key":"1200_CR173","doi-asserted-by":"publisher","first-page":"2880","DOI":"10.1182\/blood-2024-199170","volume":"144","author":"AT Fathi","year":"2024","unstructured":"Fathi, A. T. et al. Ziftomenib Combined with Venetoclax\/Azacitidine in Relapsed\/Refractory NPM1-m or KMT2A-r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET-007. Blood 144, 2880\u20132880 (2024).","journal-title":"Blood"},{"key":"1200_CR174","unstructured":"Harry Erba E. W. et al. ZIFTOMENIB COMBINED WITH INTENSIVE INDUCTION CHEMOTHERAPY (7+3) IN NEWLY DIAGNOSED NPM1-M OR KMT2A-R ACUTE MYELOID LEUKEMIA (AML): UPDATED PHASE 1A\/B RESULTS FROM KOMET-007 [EB\/OL] 2025, https:\/\/library.ehaweb.org\/eha\/2025\/eha2025-congress\/4159213\/harry.erba.ziftomenib.combined.with.intensive.induction.chemotherapy.2872B329.in.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3DZIFTOMENIB."},{"key":"1200_CR175","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1182\/blood-2024-207106","volume":"144","author":"E Searle","year":"2024","unstructured":"Searle, E. et al. Bleximenib dose optimization and determination of RP2D from a phase 1 study in relapsed\/refractory acute leukemia patients with KMT2A and NPM1 alterations. Blood 144, 212\u2013212 (2024).","journal-title":"Blood"},{"key":"1200_CR176","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1182\/blood-2024-207072","volume":"144","author":"C Recher","year":"2024","unstructured":"Recher, C. et al. Phase 1b Study of Menin-KMT2A Inhibitor Bleximenib in Combination with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with KMT2Ar or NPM1 Alterations. Blood 144, 215\u2013215 (2024).","journal-title":"Blood"},{"key":"1200_CR177","unstructured":"Andrew, H. et al. RP2D DETERMINATION OF BLEXIMENIB IN COMBINATION WITH VEN+AZA: PHASE 1B STUDY IN ND & R\/R AML WITH KMT2A\/NPM1 ALTERATIONS [EB\/OL] 2025, https:\/\/library.ehaweb.org\/eha\/2025\/eha2025-congress\/4159214\/andrew.h.wei.rp2d.determination.of.bleximenib.in.combination.with.ven2Baza.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3DBLEXIMENIB."},{"key":"1200_CR178","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1182\/blood-2024-198959","volume":"144","author":"D Wu","year":"2024","unstructured":"Wu, D. et al. A First-in-Human Phase 1\/2 Study of the Menin-KMT2A(MLL1) Inhibitor BN104 in Adult Patients with Relapsed or Refractory Acute Leukemia. Blood 144, 2879\u20132879 (2024).","journal-title":"Blood"},{"key":"1200_CR179","doi-asserted-by":"crossref","unstructured":"Daver, N. et al. Phase 1\/2 First-in-Human Study of the Menin- MLL Inhibitor DSP-5336 in Patients with Relapsed or Refractory Acute Leukemia. Blood. 142 (2023).","DOI":"10.1182\/blood-2023-179252"},{"key":"1200_CR180","doi-asserted-by":"crossref","unstructured":"Lancet, J. et al. Covalent Menin Inhibitor Bmf-219 in Patients with Relapsed or Refractory (R\/R) Acute Leukemia (AL): Preliminary Phase 1 Data from the Covalent-101 Study. Blood. 142 (2023).","DOI":"10.1182\/blood-2023-173149"},{"key":"1200_CR181","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.114901","volume":"43","author":"EB Heikamp","year":"2024","unstructured":"Heikamp, E. B. et al. NUP98 fusion proteins and KMT2A-MENIN antagonize PRC1.1 to drive gene expression in AML. Cell Rep. 43, 114901 (2024).","journal-title":"Cell Rep."},{"key":"1200_CR182","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1182\/blood.2023023644","volume":"144","author":"X Zhou","year":"2024","unstructured":"Zhou, X. et al. Epigenetic regulation of noncanonical menin targets modulates menin inhibitor response in acute myeloid leukemia. Blood 144, 2018\u20132032 (2024).","journal-title":"Blood"},{"key":"1200_CR183","doi-asserted-by":"crossref","unstructured":"Mahdavi, L. et al. Upfront menin-inhibitor resistance in multiply pretreated leukemias. Exp. Hematol. 2025:105268.","DOI":"10.1016\/j.exphem.2025.105268"},{"key":"1200_CR184","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.ccr.2008.10.001","volume":"14","author":"AV Krivtsov","year":"2008","unstructured":"Krivtsov, A. V. et al. H3K79 methylation profiles define murine and human MLL-AF4 leukemias. Cancer Cell 14, 355\u2013368 (2008).","journal-title":"Cancer Cell"},{"key":"1200_CR185","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.1182\/blood-2012-11-465120","volume":"121","author":"AJ Deshpande","year":"2013","unstructured":"Deshpande, A. J. et al. Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l. Blood 121, 2533\u20132541 (2013).","journal-title":"Blood"},{"key":"1200_CR186","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.ccell.2014.10.009","volume":"26","author":"AJ Deshpande","year":"2014","unstructured":"Deshpande, A. J. et al. AF10 regulates progressive H3K79 methylation and HOX gene expression in diverse AML subtypes. Cancer Cell 26, 896\u2013908 (2014).","journal-title":"Cancer Cell"},{"key":"1200_CR187","doi-asserted-by":"crossref","unstructured":"Grigsby, S. M. et al. Elucidating the Importance of DOT1L Recruitment in MLL-AF9 Leukemia and Hematopoiesis. Cancers. 13 (2021).","DOI":"10.3390\/cancers13040642"},{"key":"1200_CR188","doi-asserted-by":"publisher","first-page":"e190","DOI":"10.3324\/haematol.2014.115337","volume":"100","author":"MW K\u00fchn","year":"2015","unstructured":"K\u00fchn, M. W. et al. MLL partial tandem duplication leukemia cells are sensitive to small molecule DOT1L inhibition. Haematologica 100, e190\u2013e193 (2015).","journal-title":"Haematologica"},{"key":"1200_CR189","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ccr.2011.06.009","volume":"20","author":"SR Daigle","year":"2011","unstructured":"Daigle, S. R. et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell 20, 53\u201365 (2011).","journal-title":"Cancer Cell"},{"key":"1200_CR190","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms2304","volume":"3","author":"W Yu","year":"2012","unstructured":"Yu, W. et al. Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors. Nat. Commun. 3, 1288 (2012).","journal-title":"Nat. Commun."},{"key":"1200_CR191","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1038\/leu.2012.327","volume":"27","author":"L Chen","year":"2013","unstructured":"Chen, L. et al. Abrogation of MLL-AF10 and CALM-AF10-mediated transformation through genetic inactivation or pharmacological inhibition of the H3K79 methyltransferase Dot1l. Leukemia 27, 813\u2013822 (2013).","journal-title":"Leukemia"},{"key":"1200_CR192","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2019.112023","volume":"189","author":"GS Gibbons","year":"2020","unstructured":"Gibbons, G. S. et al. Identification of DOT1L inhibitors by structure-based virtual screening adapted from a nucleoside-focused library. Eur. J. Med. Chem. 189, 112023 (2020).","journal-title":"Eur. J. Med. Chem."},{"key":"1200_CR193","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1182\/blood.2020006113","volume":"136","author":"F Perner","year":"2020","unstructured":"Perner, F. et al. Novel inhibitors of the histone methyltransferase DOT1L show potent antileukemic activity in patient-derived xenografts. Blood 136, 1983\u20131988 (2020).","journal-title":"Blood"},{"key":"1200_CR194","doi-asserted-by":"publisher","first-page":"7770","DOI":"10.1021\/acs.jmedchem.2c00083","volume":"65","author":"Y Yuan","year":"2022","unstructured":"Yuan, Y. et al. Design, synthesis, and biological evaluations of DOT1L peptide mimetics targeting the protein-protein interactions between DOT1L and MLL-AF9\/MLL-ENL. J. Med Chem. 65, 7770\u20137785 (2022).","journal-title":"J. Med Chem."},{"key":"1200_CR195","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1182\/blood.V128.22.2780.2780","volume":"128","author":"N Shukla","year":"2016","unstructured":"Shukla, N. et al. Final Report of Phase 1 Study of the DOT1L Inhibitor, Pinometostat (EPZ-5676), in Children with Relapsed or Refractory MLL-r Acute LeukemiaDOT1L Inhibitor, Pinometostat (EPZ-5676), in Children with Relapsed or Refractory MLL-r Acute Leukemia. Blood 128, 2780\u20132780 (2016).","journal-title":"Blood"},{"key":"1200_CR196","doi-asserted-by":"publisher","first-page":"2661","DOI":"10.1182\/blood-2017-12-818948","volume":"131","author":"EM Stein","year":"2018","unstructured":"Stein, E. M. et al. The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia. Blood 131, 2661\u20132669 (2018).","journal-title":"Blood"},{"key":"1200_CR197","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1124\/jpet.114.214577","volume":"350","author":"CR Klaus","year":"2014","unstructured":"Klaus, C. R. et al. DOT1L inhibitor EPZ-5676 displays synergistic antiproliferative activity in combination with standard of care drugs and hypomethylating agents in MLL-rearranged leukemia cells. J. Pharm. Exp. Ther. 350, 646\u2013656 (2014).","journal-title":"J. Pharm. Exp. Ther."},{"key":"1200_CR198","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1038\/leu.2016.327","volume":"31","author":"C Dafflon","year":"2017","unstructured":"Dafflon, C. et al. Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia. Leukemia 31, 1269\u20131277 (2017).","journal-title":"Leukemia"},{"key":"1200_CR199","doi-asserted-by":"crossref","unstructured":"Adriaanse, F. R. S. et al. Distinct Responses to Menin Inhibition and Synergy with DOT1L Inhibition in KMT2A-Rearranged Acute Lymphoblastic and Myeloid Leukemia. Int. J. Mol. Sci. 25 (2024).","DOI":"10.3390\/ijms25116020"},{"key":"1200_CR200","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1038\/nature09504","volume":"468","author":"P Filippakopoulos","year":"2010","unstructured":"Filippakopoulos, P. et al. Selective inhibition of BET bromodomains. Nature 468, 1067\u20131073 (2010).","journal-title":"Nature"},{"key":"1200_CR201","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/nature10334","volume":"478","author":"J Zuber","year":"2011","unstructured":"Zuber, J. et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 478, 524\u2013528 (2011).","journal-title":"Nature"},{"key":"1200_CR202","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1007\/s12015-020-10057-y","volume":"16","author":"J Zha","year":"2020","unstructured":"Zha, J. et al. Disruption of CTCF Boundary at HOXA Locus Promote BET Inhibitors\u2019 Therapeutic Sensitivity in Acute Myeloid Leukemia. Stem Cell Rev. Rep. 16, 1280\u20131291 (2020).","journal-title":"Stem Cell Rev. Rep."},{"key":"1200_CR203","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nature11606","volume":"492","author":"MT McCabe","year":"2012","unstructured":"McCabe, M. T. et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 492, 108\u2013112 (2012).","journal-title":"Nature"},{"key":"1200_CR204","doi-asserted-by":"crossref","unstructured":"Lambert, M. et al. Direct and indirect targeting of HOXA9 transcription factor in acute myeloid leukemia. Cancers (2019).","DOI":"10.3390\/cancers11060837"},{"key":"1200_CR205","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1021\/acs.jmedchem.8b01448","volume":"62","author":"S Depauw","year":"2019","unstructured":"Depauw, S. et al. Heterocyclic Diamidine DNA Ligands as HOXA9 Transcription Factor Inhibitors: Design, Molecular Evaluation, and Cellular Consequences in a HOXA9-Dependant Leukemia Cell Model. J. Med Chem. 62, 1306\u20131329 (2019).","journal-title":"J. Med Chem."},{"key":"1200_CR206","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.77","volume":"8","author":"M Lambert","year":"2024","unstructured":"Lambert, M. et al. Induction of AML cell differentiation using HOXA9\/DNA binding inhibitors as a potential therapeutic option for HOXA9-dependent AML. Hemasphere 8, e77 (2024).","journal-title":"Hemasphere"},{"key":"1200_CR207","unstructured":"Julie Vrevin M. L., Nathalie Jouy, Marie-Helene DAVID-CORDONNIER. DIRECT FUNCTIONAL HOXA9\/DNA BINDING COMPETITORS VERSUS EPIGENETIC INHIBITORS OF HOXA9 EXPRESSION ON CELL PROLIFERATION, DEATH AND DIFFERENTIATION PROCESSES IN THE MODEL OF MLL-REARRANGED ACUTE MYELOID LEUKAEMIA [EB\/OL] 2025, https:\/\/library.ehaweb.org\/eha\/2025\/eha2025-congress\/4160504\/marie-helene.david-cordonnier.direct.functional.hoxa9.dna.binding.competitors.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3DHOXA9."},{"key":"1200_CR208","doi-asserted-by":"publisher","first-page":"5806","DOI":"10.1158\/0008-5472.CAN-06-4231","volume":"67","author":"R Morgan","year":"2007","unstructured":"Morgan, R. et al. Antagonism of HOX\/PBX dimer formation blocks the in vivo proliferation of melanoma. Cancer Res 67, 5806\u20135813 (2007).","journal-title":"Cancer Res"},{"key":"1200_CR209","doi-asserted-by":"publisher","first-page":"S133","DOI":"10.1016\/S0959-8049(16)32994-X","volume":"69","author":"M Primon","year":"2016","unstructured":"Primon, M., Hoffman, E., Pandha, H. S. & Morgan, R. HTL001, a novel inhibitor of HOX\/PBX binding, is highly cytotoxic to prostate and breast cancer cells. Eur. J. Cancer 69, S133\u2013S133 (2016).","journal-title":"Eur. J. Cancer"},{"key":"1200_CR210","doi-asserted-by":"crossref","unstructured":"Fu, J. F., Shih, L. Y. & Yen, T. H. HOXA11 plays critical roles in disease progression and response to cytarabine in AML. Oncol Rep. 46 (2021).","DOI":"10.3892\/or.2021.8101"},{"key":"1200_CR211","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1089\/scd.2011.0259","volume":"21","author":"M Fournier","year":"2012","unstructured":"Fournier, M., Lebert-Ghali, C., Krosl, G. & Bijl, J. J. HOXA4 induces expansion of hematopoietic stem cells in vitro and confers enhancement of pro-B-cells in vivo. Stem Cells Dev. 21, 133\u2013142 (2012).","journal-title":"Stem Cells Dev."},{"key":"1200_CR212","doi-asserted-by":"publisher","first-page":"3391","DOI":"10.1182\/blood.V93.10.3391.410k26_3391_3400","volume":"93","author":"JF Fuller","year":"1999","unstructured":"Fuller, J. F. et al. Characterization of HOX gene expression during myelopoiesis: role of HOX A5 in lineage commitment and maturation. Blood 93, 3391\u20133400 (1999).","journal-title":"Blood"},{"key":"1200_CR213","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.1182\/blood-2014-03-558825","volume":"124","author":"V Ramos-Mej\u00eda","year":"2014","unstructured":"Ramos-Mej\u00eda, V. et al. HOXA9 promotes hematopoietic commitment of human embryonic stem cells. Blood 124, 3065\u20133075 (2014).","journal-title":"Blood"},{"key":"1200_CR214","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/bjh.13949","volume":"173","author":"IM Konieczna","year":"2016","unstructured":"Konieczna, I. M., DeLuca, T. A., Eklund, E. A. & Miller, W. M. Hoxa10 null animals exhibit reduced platelet biogenesis. Br. J. Haematol. 173, 303\u2013313 (2016).","journal-title":"Br. J. Haematol."}],"container-title":["npj Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41698-025-01200-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-025-01200-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-025-01200-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T15:04:08Z","timestamp":1765206248000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41698-025-01200-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":214,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1200"],"URL":"https:\/\/doi.org\/10.1038\/s41698-025-01200-4","relation":{},"ISSN":["2397-768X"],"issn-type":[{"value":"2397-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,5]]},"assertion":[{"value":"11 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"396"}}